{
  "id": "589a246a78275d0c4a000031",
  "type": "summary",
  "question": "What is the mechanism of action of verubecestat?",
  "ideal_answer": "Verubecestat (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
    "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
    "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
    "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
    "http://www.ncbi.nlm.nih.gov/pubmed/27934506"
  ],
  "snippets": [
    {
      "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat is an inhibitor of \u03b2-secretase being evaluated for the treatment of Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chronic treatment of rats and monkeys with verubecestat achieved exposures >40-fold higher than those being tested in clinical trials in AD patients yet did not elicit many of the adverse effects previously attributed to BACE inhibition, such as reduced nerve myelination, neurodegeneration, altered glucose homeostasis, or hepatotoxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27934506",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A \u03b2-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "After giving an update on the development and current status of new AD therapeutics, this review will focus on BACE inhibitors and, in particular, will discuss the prospects of verubecestat (MK-8931), which has reached phase III clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although not selective over the closely related aspartyl protease BACE2, verubecestat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain A\u03b2 levels in rats and nonhuman primates and CSF A\u03b2 levels in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
  ]
}